139927-84-7

Upstream product

• 41078-01-7 3-Ethylxanthine 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 80798-51-2 6-amino-1-ethyl-5-nitrosopyrimidine-2,4(1H,3H)-dione 
• 41862-09-3 1-ethyl-6-aminouracil 
• 64-18-6 formic acid 
• 80798-52-3 5,6-diamino-1-ethyl-2,4(1H,3H)-pyrimidinedione 
• 115377-59-8 1-benzyl-4-(N-ethylamino)-1H-imidazole-5-carboxamide 
• 139927-87-0 1-benzyl-4-<(ethoxycarbonyl)ethylamino>-1H-imidazole-5-carboxamide 

Downstream Products

• 139927-97-2 7-Benzyl-3-ethyl-1-methyl-3,7-dihydro-purine-2,6-dione 
• 190262-91-0 diethyl [4-(7-benzyl-3-ethylxanthin-1-yl)butyl]phosphonate 
• 200487-08-7 7-Benzyl-1-sec-butoxymethyl-3-ethylxanthine 
• 200487-12-3 7-benzyl-3-ethyl-1-(2-(2-methoxyethoxy)ethyl)xanthine 
• 170155-79-0 7-Benzyl-3-ethyl-1-(4-oxopentyl)xanthine 

Relevant academic research and scientific papers

SUBSTITUTED XANTHINE DERIVATIVES

The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.

Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation

Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation. Tertiary 1-(hydroxyalkyl)-4-alkylxanthines are suitable for the production of pharmaceuticals for the treatment of disorders which is associated with a pathologically increased reactivity of eosinophilic granulocytes. Novel xanthine derivatives and process for their preparation are described.

Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Use of theophylline derivatives for the treatment and prophylaxis of states of shock, novel xanthine compounds and processes for their preparation

Theophylline derivatives having at least one ether function in the structurally modified methyl radical in the 1-position that are useful in the treatment and prophylaxis of states of shock, new xanthine compounds having this substitution pattern, and processes for their preparation.

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals A compound of the formula STR1 where R1 and R3 are identical or different and at least one of the radicals R1 and R3 is a radical of the formula XI STR2 in which E is a covalent bond or a (C1 -C5)-alkyl, are suitable for the production of pharmaceuticals for the treatment of muscular atrophy, cachexia, muscular dystrophy, sepsis, septic shock, endotoxic shock, systemic inflammation response syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pneumonia, pulmonary sarcoidosis, reperfusion damage, scar formation, inflammation of the bowel and ulcerative colitis, as a result of infections, acquired immune deficiency syndrome, cancer, trauma and other disorders having increased protein loss, peripheral circulatory disorders, disorders having altered leucocyte adhesion, and also disorders which are accompanied by an increased or unregulated tumor necrosis factor production such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic disorders.

Purines. XLIX. Synthesis and proton nuclear magnetic resonance study of 3,7-dialkylxanthines and 1,3,7-trialkylxanthines

A general synthetic route to 3,7-dialkylxanthines (type 9) from 3,7-dialkyladenines (6) [hence from 3- or 7-alkyladenines (11 or 10)] has been established. The route started with ethoxycarbonylation of 1-alkyl-4-(alkylamino)1H-imidazole-5-carboxamides (7), readily obtainable from 6 by alkaline hydrolysis, and proceeded through cyclization of the resulting carbamates (8) under alkaline conditions. Alkylation of 9 with alkyl halide in N,N-dimethylformamide in the presence of anhydrous K2CO3 extended the above synthetic route to the 1,3,7-trialkylxanthine level (type 14). Hydrogenolytic deb nzylation of 3-benzyl-1,7-dimethylxanthine (16), prepared by following this general synthetic route, furnished paraxanthine (26) in fair yield. Conversion of 26 into 3-(4-hydroxy-3-nitrobenzyl)-1,7-dimethylxanthine (24), isomeric with the bryozoan purine phidolopin (2), was effected through aralkylation with 4-(methoxymethoxy)-3-nitrobenzyl bromide (28) followed by O-deprotection. On the basis of proton nuclear magnetic resonance data for the 3,7-dialkylxanthines (3 and 9b-i) and 1,3,7-trialkylxanthines (5 and 14-22) thus prepared, reliable criteria for distinguishing signals of N-alkyl substituents at various positions are put forward.